Ultragenyx Pharmaceutical RARE Institutional Ownership

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is held by 308 institutional investors per 13F filings through June 2026.

• Collectively, these holders controlled 105.4% of Ultragenyx Pharmaceutical's outstanding shares in June 2026, up from 97.6% in March 2026.
• Their total shares held in RARE increased 15.26% from the prior quarter, while the number of investors in Ultragenyx Pharmaceutical increased 0.33% year over year.
• Of these 308 funds, 172 grew their exposure to Ultragenyx Pharmaceutical, 98 cut back, and 38 maintained positions.
• Combined, these investors held 107.44Mn shares in RARE for June 2026, up by 14.22Mn shares quarter on quarter, and up 13.23Mn shares year over year.
• BlackRock, Inc. holds the largest position in RARE at 10.65Mn shares as of June 30, 2026, or 10.46% of shares outstanding.
• The biggest buyers of Ultragenyx Pharmaceutical for the quarter ending June 2026 included RTW INVESTMENTS, LP (4.15Mn), BlackRock, Inc. (3.35Mn), AQR CAPITAL MANAGEMENT LLC (1.98Mn), JACOBS LEVY EQUITY MANAGEMENT, INC (1.51Mn), MPM BioImpact LLC (1.42Mn).
• The largest sellers of Ultragenyx Pharmaceutical for the quarter ending June 2026 were Assenagon Asset Management S.A. (2.14Mn), CITADEL ADVISORS LLC (1.9Mn), Sofinnova Investments, Inc. (1.43Mn), WELLINGTON MANAGEMENT GROUP LLP (1.39Mn), MILLENNIUM MANAGEMENT LLC (1.01Mn).
• Per Business Quant data, the top 10 holders of Ultragenyx Pharmaceutical for the quarter ending June 2026 are BlackRock, Inc. (10.65Mn), RTW INVESTMENTS, LP (7.8Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (6.79Mn), AQR CAPITAL MANAGEMENT LLC (6.56Mn), State Street Corp (6.16Mn), VANGUARD CAPITAL MANAGEMENT LLC (4.3Mn), TWO SIGMA INVESTMENTS, LP (3.62Mn), SANDS CAPITAL MANAGEMENT, LLC (3.16Mn), JACOBS LEVY EQUITY MANAGEMENT, INC (2.94Mn), FRONTIER CAPITAL MANAGEMENT CO LLC (2.85Mn).